My HappyStock
Log in to track your learning progress.
US Companies
Find my preferred stocks →Compare companies across six criteria and explore businesses that fit your priorities.
Eli Lilly and Company (LLY)
Average score 8.5 A
Preference —
Six company scores
Mounjaro and Zepbound demand fuels rapid expansion
High-margin drugs and scale enhance profitability
AA- credit and cash generation offset debt burdens
Patents, clinical data and capacity protect market share
Oral obesity drugs offer upside; pricing risks remain
About 29x forward earnings prices in strong growth
Editorial scores are for education, not audited financial metrics or investment advice.
Revenue by business
- Mounjaro 43.95%
Tirzepatide for type 2 diabetes
- Zepbound 21.94%
Tirzepatide for obesity and weight management
- Jardiance 6.47%
Partnered diabetes, heart and kidney disease drug
- Verzenio 6.19%
Breast cancer therapy targeting HR+/HER2-
- Trulicity 3.7%
Weekly GLP-1 treatment for type 2 diabetes
- Taltz 3.51%
Therapy for psoriasis and psoriatic arthritis
- Other Products and Collaborations 14.24%
Includes Kisunla, Jaypirca and oral obesity drugs
Revenue by region
- United States 62.04%
- Europe 18.28%
- China 3.88%
- Japan 2.66%
- Rest of World 13.14%
Key metrics
| Revenue CAGR (5 years) | 22% |
|---|---|
| Operating income CAGR (5 years) | 34% |
| Net income CAGR (5 years) | 27% |
| Operating margin (5-year avg.) | 27% |
| ROE (5-year avg.) | 74% |
| ROA (5-year avg.) | 14% |
| Beta (5 years) | 0.39 |
| MDD (5 years) | -35% |
| Payout ratio (5-year avg.) | 52% |
| P/E | 44x |
| Forward P/E | 29x |
| PEG | 1.39 |